Compare AANJANEYA LIFECARE with Jubilant Pharmova - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs JUBILANT PHARMOVA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS JUBILANT PHARMOVA DR. DATSONS LABS/
JUBILANT PHARMOVA
 
P/E (TTM) x -10.9 13.1 - View Chart
P/BV x 0.2 2.5 6.6% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 DR. DATSONS LABS   JUBILANT PHARMOVA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
JUBILANT PHARMOVA
Mar-19
DR. DATSONS LABS/
JUBILANT PHARMOVA
5-Yr Chart
Click to enlarge
High Rs126898 14.0%   
Low Rs31618 5.0%   
Sales per share (Unadj.) Rs133.0572.0 23.3%  
Earnings per share (Unadj.) Rs0.236.2 0.4%  
Cash flow per share (Unadj.) Rs6.659.5 11.1%  
Dividends per share (Unadj.) Rs04.50 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs128.8301.9 42.7%  
Shares outstanding (eoy) m31.66159.28 19.9%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.61.3 44.4%   
Avg P/E ratio x516.120.9 2,467.5%  
P/CF ratio (eoy) x11.812.7 93.0%  
Price / Book Value ratio x0.62.5 24.2%  
Dividend payout %012.4 0.0%   
Avg Mkt Cap Rs m2,477120,694 2.1%   
No. of employees `000NA2.4 0.0%   
Total wages/salary Rs m5619,260 0.3%   
Avg. sales/employee Rs ThNM38,120.6-  
Avg. wages/employee Rs ThNM8,058.4-  
Avg. net profit/employee Rs ThNM2,414.3-  
INCOME DATA
Net Sales Rs m4,21191,108 4.6%  
Other income Rs m79357 22.0%   
Total revenues Rs m4,28991,466 4.7%   
Gross profit Rs m56917,390 3.3%  
Depreciation Rs m2043,709 5.5%   
Interest Rs m4302,198 19.6%   
Profit before tax Rs m1311,840 0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m63,268 0.2%   
Profit after tax Rs m55,770 0.1%  
Gross profit margin %13.519.1 70.8%  
Effective tax rate %48.027.6 174.0%   
Net profit margin %0.16.3 1.8%  
BALANCE SHEET DATA
Current assets Rs m6,85245,848 14.9%   
Current liabilities Rs m6,71120,897 32.1%   
Net working cap to sales %3.327.4 12.2%  
Current ratio x1.02.2 46.5%  
Inventory Days Days16157 283.2%  
Debtors Days Days31851 625.2%  
Net fixed assets Rs m3,67365,498 5.6%   
Share capital Rs m317159 198.7%   
"Free" reserves Rs m3,76147,930 7.8%   
Net worth Rs m4,07848,089 8.5%   
Long term debt Rs m1,67142,429 3.9%   
Total assets Rs m12,633114,685 11.0%  
Interest coverage x1.06.4 16.1%   
Debt to equity ratio x0.40.9 46.4%  
Sales to assets ratio x0.30.8 42.0%   
Return on assets %3.46.9 49.6%  
Return on equity %0.112.0 1.0%  
Return on capital %7.712.4 61.8%  
Exports to sales %22.90-   
Imports to sales %14.30-   
Exports (fob) Rs m964NA-   
Imports (cif) Rs m602NA-   
Fx inflow Rs m96412,422 7.8%   
Fx outflow Rs m60717,227 3.5%   
Net fx Rs m357-4,805 -7.4%   
CASH FLOW
From Operations Rs m1,34511,215 12.0%  
From Investments Rs m-2,256-10,118 22.3%  
From Financial Activity Rs m-1,2006,574 -18.2%  
Net Cashflow Rs m-2,1117,612 -27.7%  

Share Holding

Indian Promoters % 4.5 45.6 9.9%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 0.0 8.7 -  
FIIs % 1.4 21.2 6.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 21.1 446.0%  
Shareholders   20,807 23,815 87.4%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   SANOFI INDIA  ABBOTT INDIA  DISHMAN PHARMA  CIPLA  TORRENT PHARMA  

Compare DR. DATSONS LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 661 Points, Nifty Ends Above 14,500; M&M and Bajaj Finserv Top Gainers(Closing)

Indian share markets witnessed most of the buying interest during closing hours today and ended on a strong note.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

Nazara Technologies IPO: Should You Apply? (IPO)

Mar 17, 2021

Should you bet on this gaming company backed by ace investor Rakesh Jhunjhunwala?

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

More Views on News

Most Popular

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

If the Market Falls, I Will Do This...(Fast Profits Daily)

Apr 1, 2021

What should you do if the market falls? In this video, I'll tell you what I will do.

The Indian Real Estate Party Has Just Begun(Profit Hunter)

Apr 1, 2021

A favourable demand supply scenario makes a strong case for real estate prices.

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

The Dilemma of Investing in Bharti Airtel(Views On News)

Apr 1, 2021

Rahul Shah on whether Bharti Airtel will emerge as the next big thing in the Indian stock market

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS - NOVARTIS COMPARISON

COMPARE DR. DATSONS LABS WITH

MARKET STATS